Hadassah

Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome

Monday, Oct 24 2011

"In pre-clinical studies," notes Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory at the Sharrett Institute of Oncology at Hadassah University Medical Center, "we found that placental-derived cells potentially have the ability to increase the survival rate of animals following exposure to lethal doses of total body irradiation."

These placental (PLX) cells, developed by Pluristem Therapeutics Inc., treat life-threatening complications associated with Acute Radiation Syndrome (ARS).

During the studies, animals were injected intravenously with either PLX cells or a placebo, on the day after being exposed to lethal doses of radiation. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals. Overall survival and body weight changes were also monitored. The researchers found in the animals treated with the PLX cells:

  • an up to four-fold increase in the survival rate accompanied by a corresponding weight regain
  • an increase in red-cell count on days 21-23
  • an elevated number of hematopoietic colonies on day 9

Over the next few months, Prof. Gorodetsky and his team will focus on better understanding the PLX cells' mechanism of action as an "off the shelf" post radiation treatment, which could potentially be used in the future for treating ARS patients.

"While our experiments using PLX cells in treating radiation exposure are ongoing and still evolving, these initial data are very encouraging," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "PLX cells as a sole treatment may potentially enhance the survival of lethally irradiated individuals. Moreover, since our previous work indicated that PLX cells can enhance the engraftment of hematopoietic stem cells from cord blood, we can offer a multifaceted approach to reduce and treat the destruction of bone marrow that occurs following exposure to high-dose ionizing radiation. Stockpiled PLX cells can be administered acutely and as a bridging therapy to protect the bone marrow."

Related Stories

alt_text

Thursday, Jul 2 2020

Leading a COVID-19-Free Hospital–a Vision Beyond the Virus at Hadassah

In the midst of the COVID-19 pandemic, Dr. Tamar Elram, director of Hadassah Hospital Mount Scopus, has been in the very unusual situation of running a large hospital...

READ MORE ›
alt_text

Wednesday, Jul 1 2020

Hadassah Colloquium Assesses Where We Are Headed With COVID-19

As frightening numbers of new COVID-19 cases plague Israel, Prof. Allon Moses, international infectious disease expert and immediate past director of the Hadassah Medical...

READ MORE ›
alt_text

Monday, Jun 29 2020

First Commercial Antibody Serum Given at Hadassah to COVID-19 Patient

The Hadassah Medical Organization worked with an ultra-Orthodox communal organization to collect antibody-rich plasma from recovered COVID-19 patients...

READ MORE ›
alt_text

Monday, Jun 29 2020

COVID-19 Nursing Care Leads to Collaborative Research by Hadassah Nurses

With a little distance from the first phase of the COVID-19 pandemic, Hadassah Medical Organization nurse educator and critical care specialist Julie Benbenishty...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More